Knowledge of status and assessment of personal health consequences with hepatitis C are not enough to change risk behaviour among injecting drug users in Stockholm County, Sweden

Scandinavian Journal of Infectious Diseases

Volumn 41, Issue 10, 2009, Pages 727-734

  Norden, Lillebil ^a,b   Saxon, Lars ^a,b   Kåberg, Martin ^c   Käll, Kerstin ^d   Franck, Johan ^a   Lidman, Christer ^a,b  

^a KAROLINSKA INSTITUTE   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c Maria Addiction Centre   (Sweden)

^d University Hospital   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHETAMINE; DIAMORPHINE;

ADOLESCENT; ADULT; ARTICLE; AWARENESS; CONCEPTUAL FRAMEWORK; DRUG ABUSE; FEMALE; GROUPS BY AGE; HEPATITIS C; HIGH RISK BEHAVIOR; HUMAN; INFECTION RISK; KNOWLEDGE; MAJOR CLINICAL STUDY; MALE; NEEDLE; RISK ASSESSMENT; SELF REPORT; SEXUAL BEHAVIOR; SWEDEN;

ADOLESCENT; ADULT; FEMALE; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HEPATITIS C; HUMANS; MALE; NEEDLE SHARING; RISK-TAKING; SUBSTANCE ABUSE, INTRAVENOUS; SWEDEN;

EID: 72449194823     PISSN: 00365548     EISSN: 16511980     Source Type: Journal    
DOI: 10.1080/00365540903159279     Document Type: Article

References (25)

1. Alter MJ,Moyer LA. The importance of preventing hepatitis C virus infection among injection drug users in the United States. J Acquir Immune Defic Syndr Hum Retrovirol 1998;/ 18(Suppl 1):/S6-10.
2. Bruandet A, Lucidarme D, Decoster A, Ilef D, Harbonnier J, Jacob C, et al. Incidence and risk factors of HCV infection in a cohort of intravenous drug users in the north and east of France. Rev Epidemiol Sante Publique 2006;/54(Spec No 1):/ S15-22.
3. Lucidarme D, Bruandet A, Ilef D, Harbonnier J, Jacob C, Decoster A, et al. Incidence and risk factors of HCV and HIV infections in a cohort of intravenous drug users in the North and East of France. Epidemiol Infect 2004;/132:/699- 708.
4. Maher L, Li J, Jalaludin B, Chant KG, Kaldor JM. High hepatitis C incidence in new injecting drug users: a policy failure? Aust N Z J Public Health 2007;/31:/30-5.
5. Thorpe LE, Ouellet LJ, Hershow R, Bailey SL, Williams IT, Williamson J, et al. Risk of hepatitis C virus infection among young adult injection drug users who share injection equipment. Am J Epidemiol 2002;/155:/645-53.
6. Strauss SM, Astone-Twerrell J, Munoz-Plaza CE, Des Jarlais DC, Gwadz M, Hagan H, et al. Drug treatment program patients' hepatitis C virus (HCV) education needs and their use of available HCV education services. BMC Health Serv Res 2007;/7:/39.
7. Rhodes T, Davis M, Judd A. Hepatitis C and its risk management among drug injectors in London: renewing harm reduction in the context of uncertainty. Addiction 2004;/99:/621-33.
8. Kwiatkowski CF, Fortiun Corsi K, Booth RE. The association between knowledge of hepatitis C virus status and risk behaviors in injection drug user. Addiction 2002;/97:/1289- 94.
9. Slovic P, Weber E. Perception of risk posed by extreme events. Risk management strategies in an uncertain world. New York: Palisades; 2002.
10. Norden L, Lidman C. Differentiated risk behaviour for HIV and hepatitis among injecting drug users (IDUs). Scand J Infect Dis 2005;/37:/493-6.
11. Miller PG. Scapegoating, self-confidence and risk comparison: the functionality of risk neutralisation and lay epidemiology by injecting drug users. Int J Drug Policy 2005;/16:/ 246-253
12. Loewenstein GF, Weber EU, Hsee CK, Welch N. Risk as feelings. Psychol Bull 2001;/127:/267-86.
13. Läkarinformatin hepatit C, 2004-2007-01. Smittskyddslä karföreninge 2007. Available from http://www.smittskyddsinstitutet.se.
14. CAN Rapport 113, Drogutreckling i Sverige. 2008; 128. Available from http://www.can.se.
15. Lidman C, Norden L, Kaberg M, Käll K, Franck J, Aleman S, et al. Hepatitis C infection among injection drug users in Stockholm Sweden: prevalence and gender. Scand J Infect Dis; in press.
16. Maher L, Jalaludin B, Chant KG, Jayasuriya R, Sladden T, Kaldor JM, et al. Incidence and risk factors for hepatitis C seroconversion in injecting drug users in Australia. Addiction 2006;/101:/1499-508.
17. Miller CL, Johnston C, Spittal PM, Li K, Laliberte N, Montaner JS, et al. Opportunities for prevention: hepatitis C prevalence and incidence in a cohort of young injection drug users. Hepatology 2002;/36:/737-42.
18. Hagan H, Campbell J, Thiede H, Strathdee S, Ouellet L, Kapadia F, et al. Self-reported hepatitis C virus antibody status and risk behaviour in young injectors. Public Health Rep 2006;/121:/710-9.
19. Hallinan R, Byrne A, Agho K, Gregory J, Dore GJ. Referral for chronic hepatitis C treatment from a drug dependency treatment setting. Drug Alcohol Depend 2007;/88:/49-53.
20. Läkarinformatin hepatit C, 2004-2007-01. Smittskyddslä karföreninge 2009. Available from http://www.smittskyddstockholm.se.
21. Marsch LA, Bickel WK, Badger GJ, Quesnel KJ. The anatomy of risk: a quantitative investigation into injection drug users' taxonomy of risk attitudes and perceptions. Exp Clin Psychopharmacol 2007;/15:/195-203.
22. Crisp BR, Barber JG. The effect of locus of control on the association between risk perception and sexual risk-taking. Pers Indiv Differ 1995;/19:/841-5.
23. Craine N, Walker AM, Williamson S, Brown A, Hope VD. Hepatitis B and hepatitis C seroprevalence and risk behaviour among community-recruited drug injectors in North West Wales. Commun Dis Public Health 2004;/7:/216-9.
24. Davis M, Rhodes T. Beyond prevention? Injecting drug user narratives about hepatitis C. Int J Drug Policy 2004;/15:/123- 31.
25. DRID, Table INF-2. Prevalence of HCV antibody among injecting drug users in the EU in the year of 2006, Available from http://www.emcdda.europa.nu (April, 2009)